Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps
- PMID: 28426603
- DOI: 10.1097/AOG.0000000000002002
Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps
Comment in
-
In Reply.Obstet Gynecol. 2017 May;129(5):945-946. doi: 10.1097/AOG.0000000000002003. Obstet Gynecol. 2017. PMID: 28426604 No abstract available.
Comment on
-
Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.Obstet Gynecol. 2016 Dec;128(6):1397-1402. doi: 10.1097/AOG.0000000000001738. Obstet Gynecol. 2016. PMID: 27824772
References
-
- Stringer EM, Vladutiu CJ, Batra P, Stringer JS, Menard MK. Operationalizing 17α-hydroxyprogesterone caproate to prevent recurrent preterm birth: definitions, barriers, and next steps. Obstet Gynecol 2016;128:1397–402.
-
- Goldthwaite LM, Duca L, Johnson RK, Ostendorf D, Sheeder J. Adverse birth outcomes in Colorado: assessing the impact of a statewide initiative to prevent unintended pregnancy. Am J Public Health 2015;105:e60–6.
-
- Sonfield A, Hasstedt K, Gold RB. Moving forward: family planning in the era of health reform. New York (NY): Guttmacher Institute; 2014.
-
- Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med 2016;374:843–52.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
